Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...
Reports FY24 revenue $36.13M, consensus $37.63M. “We believe that petosemtamab’s receipt of two Breakthrough Therapy designations by the FDA – ...
Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major ...
Hosted on MSN1d
Cancer treatment costs: 'I had to rob money from the money we’d set aside for my son’s wedding'Cover for high-cost cancer drugs, including Pembrolizumab, is subject to pre-authorisation and a case-by-case review, ...
The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...
A 62-year-old college lecturer who was told he had inoperable stomach cancer has revealed how he had to raid his son’s ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the ...
The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...
Inpatient immune checkpoint inhibitor treatment produces poor outcomes across cancer types, according to the largest study of its kind.
Discover insights from Summit Therapeutics' Q4 2024 earnings call, highlighting the Pfizer collaboration, ivonescimab trial expansions, and strong ...
Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback